Korean Ministry of Food and Drug announced an investigation into biotechnology company Medytox in reports that their shareholders were clinical determinants. The regulatory agency is investigating the fairness and objectivity and whether shareholders violated the Korean Pharmaceutical Affairs Act.

A Korean media outlet reported that a professor who led clinical research at a university hospital that conducted a Medtoxin trial possibly violating conflict of interest and more when the investigator’s wife purchased shares which dramatically increased in price.

Follow the link to the Korea IT Times for more information.

Source: Korea Times

Pin It on Pinterest